Table 5.
Per-pathogen Microbiological Response Rate at Follow-up: Microbiologically Evaluable Population
| Per-pathogen Microbiological Response (Documented or Presumed Eradication)a ME at FU Analysis Set |
||
|---|---|---|
| n/N1b | Delafloxacin (n = 410) | Vancomycin + Aztreonam (n = 396) |
| S. aureus | 244/248 (98.4%) | 233/239 (97.5%) |
| MRSA | 106/108 (98.1%) | 97/99 (98.0%) |
| MSSA | 140/142 (98.6%) | 136/140 (97.1%) |
| S. anginosus c | 47/47 (100.0%) | 34/35 (97.1%) |
| S. pyogenes | 18/19 (94.7%) | 15/15 (100.0%) |
| K. pneumoniae | 17/17 (100.0%) | 17/17 (100.0%) |
| P. aeruginosa | 11/11 (100.0%) | 10/10 (100.0%) |
| E. coli | 11/11 (100.0%) | 16/17 (94.1%) |
| S. haemolyticus | 12/12 (100%) | 7/7 (100%) |
| E. cloacae | 11/12 (91.7%) | 9/10 (90.0%) |
| S. agalactiae | 11/11 (100%) | 11/12 (91.7%) |
| E. faecalis | 9/10 (90.0%) | 12/13 (92.3%) |
| S. lugdunensis | 10/10 (100%) | 7/7 (100%) |
If the same pathogen is identified from both the blood and the culture of the ABSSSI, it is counted only once in the summary. Patients with both MRSA and MSSA at baseline are included once in the overall Staphylococcus aureus category. The overall count of patients with Staphylococcus aureus includes patients whose isolates were not tested for susceptibility and, therefore, do not contribute to either the MRSA or MSSA counts.
Abbreviations: ABSSSI, acute bacterial skin and skin structure infections; FU, follow-up; ME, microbiologically evaluable; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible Staphylococcus aureus.
aInvestigator-assessed response in ME at FU analysis set was the same as per-pathogen microbiological response.
bN1 = number of patients who have the given target pathogen at baseline from the ABSSSI or blood culture; n = success, which is defined as documented or presumed eradication.
cThe Staphylococcus anginosus group includes S. anginosus, S. intermedius, and S. constellatus.